Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing

Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post-ASH symposium

(2012) Omar Abdel-Wahab et al.   AMERICAN JOURNAL OF HEMATOLOGY

JAK2 Inhibitors for Myelofibrosis: Why are They Effective in Patients with and Without JAK2V617F Mutation?

(2012) Fabio P. S. Santos et al.   Anti-Cancer Agents in Medicinal Chemistry

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib

(2012) J. Mascarenhas et al.   CURRENT MEDICINAL CHEMISTRY

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors

(2012) Jasleen Randhawa et al.   Journal of Hematology & Oncology

The evolving treatment paradigm in myelofibrosis

(2012) Ruben A. Mesa   LEUKEMIA & LYMPHOMA

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study

(2011) Ayalew Tefferi et al.   JOURNAL OF CLINICAL ONCOLOGY

Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond

(2011) Alfonso Quintás-Cardama et al.   NATURE REVIEWS DRUG DISCOVERY

Genetic and Epigenetic Complexity in Myeloproliferative Neoplasms

(2011) N. C. P. Cross   Hematology-American Society of Hematology Education Program

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD

MPN-associated myelofibrosis (MPN-MF)

(2010) R.A. Mesa et al.   LEUKEMIA RESEARCH

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK2V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms

(2010) Stephen T Oh et al.   Expert Review of Hematology

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes

(2008) Aristoteles Giagounidis et al.   ANNALS OF HEMATOLOGY

Primary Myelofibrosis: Update on Definition, Pathogenesis, and Treatment

(2008) Omar I. Abdel-Wahab et al.   Annual Review of Medicine